Premium
Live‐donor liver transplantation for hepatocellular carcinoma
Author(s) -
Fan Sheung Tat
Publication year - 2007
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2007.00196.x
Subject(s) - hepatocellular carcinoma , medicine , liver transplantation , incidence (geometry) , gastroenterology , liver function , treatment modality , milan criteria , transplantation , surgery , physics , optics
Live‐donor liver transplantation (LDLT) is a valuable option for patients with hepatocellular carcinoma (HCC) because compared with deceased‐donor liver transplantation (DDLT), the tumor could be eradicated early. However, a higher incidence of recurrence is observed when the result is compared with DDLT. The difference is explained by the timing of transplant because only patients with slow HCC growth (and probably less aggressive tumors) can wait for DDLT. Nevertheless, arecent survey of results of LDLT for HCC in Asia indicated that the 3‐year survival rate is approximately 60–80%, which is better than that of any treatment modalities for inoperable HCC associated with poor liver function. LDLT for HCC is still worthwhile to pursue and deserves further evaluation.